国泰海通证券股份有限公司 关于上海毕得医药科技股份有限公司 补充确认2025年度日常关联交易的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海毕得医药科技股份有限公司（以下简称"毕得医药"或"公司"）首次公开 发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等相关法律、法规和规范性文件的规定，对毕 得医药 2025 年度日常关联交易的事项进行了专项核查，核查情况与意见如下： 一、日常关联交易基本情况 （一）基本情况概述 公司 2025 年度向关联方西格莱购买原材料、销售商品、采购设备，发生关 联交易的合计金额为 554.91 万元人民币，其中购买原材料 0.93 万元，销售商品 460.18万元，采购设备 93.80万元。2024年度，公司与西格莱发生关联交易的金 额为 592.27 万元人民币。 Liangfu Huang 自 2025 年 1 月 1 日起向公司提供咨询服务，发生关联交易的 金额为 24.00 万美元。公司拟根据其 2025 年度 ...

Group 1 - The core business of Shanghai Bid Pharmaceutical Technology Co., Ltd. focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [2] - As of September 30, 2025, the company achieved operating revenue of 979 million yuan, a year-on-year increase of 20.67%, and a net profit attributable to shareholders of 120 million yuan, up 42.79% year-on-year [2] - The company has distributed a total of 258 million yuan in dividends since its A-share listing [3] Group 2 - On December 31, Bid Pharmaceutical's stock rose by 0.66%, with a trading volume of 59.01 million yuan [1] - The financing buy-in amount on December 31 was 2.45 million yuan, while the financing repayment was 4.40 million yuan, resulting in a net financing buy-in of -1.95 million yuan [1] - The total balance of margin trading as of December 31 was 33.48 million yuan, accounting for 1.27% of the circulating market value, which is below the 30th percentile level over the past year [1]

Core Viewpoint - The financing balance of the Sci-Tech Innovation Board (STAR Market) has increased significantly, indicating a growing interest in this market segment, while the securities lending balance has decreased slightly [1][2]. Financing Balance Summary - As of December 30, the total financing balance on the STAR Market reached 273.83 billion yuan, an increase of 1.18 billion yuan from the previous trading day, marking a continuous increase for 10 consecutive trading days [1]. - The highest financing balance among STAR Market stocks is held by Cambrian (寒武纪) at 15.63 billion yuan, followed by SMIC (中芯国际) at 13.94 billion yuan and Haiguang Information (海光信息) at 7.23 billion yuan [1]. - A total of 299 stocks saw an increase in financing balance, while 294 stocks experienced a decrease. Notable increases were observed in Zhongfu Shenying (中复神鹰) at 41.71%, Ligong Navigation (理工导航) at 18.71%, and Bide Pharmaceutical (毕得医药) at 16.34% [1][2]. Securities Lending Balance Summary - The highest securities lending balance is also held by Cambrian at 36 million yuan, followed by Haiguang Information at 34 million yuan and SMIC at 27 million yuan [2]. - A total of 201 stocks saw an increase in securities lending balance, while 201 stocks experienced a decrease. Significant increases were noted in Xinhai Technology (芯海科技) at 3874.11%, Jiulian Technology (九联科技) at 757.71%, and Longda Shares (隆达股份) at 464.08% [2]. - Notably, on December 30, a new stock, C Strong (C强), was listed on the STAR Market with a financing balance of 549.14 million yuan on its first trading day [2].

Summary of Key Points Core Viewpoint - Several companies are experiencing significant shareholder reductions, indicating potential shifts in ownership and investor sentiment within the market [1]. Shareholder Reductions - Euro Continental Holdings' controlling shareholder plans to reduce holdings by no more than 1.91% [1] - Bid Medicine's shareholders, including Li Yijing, plan to collectively reduce holdings by no more than 0.95% [1] - Zhanzi Island's shareholders and Island No. 1 Fund intend to reduce holdings by no more than 1% [1] - Qifan Cable's controlling shareholder and actual controller, Zhou Gonghua, has cumulatively reduced 0.74% of company shares [1] - Furan De's shareholder Renke Partnership has reduced a total of 9.8565 million shares [1] - Guoxin Technology's shareholder, Tibet Taida, has cumulatively reduced 1.73% of company shares [1] - Bid Medicine's shareholders, including Xinxin Management, Landan Management, and Wu Bo, have collectively reduced 1.12% of company shares [1] - Other notable reductions include: - Guangdong Financial Investment has cumulatively reduced 0.91% of Guanmeng High-tech shares [1] - UW Holdings Limited has cumulatively reduced 7.4673 million shares of United Water [1] - Zhongzheng Kaiyuan and Minquan Investment have collectively reduced 1.1092 million shares of Jiancheng Zuo Na [1] - Senior management of Baitong Energy, Liu Muliang, plans to reduce no more than 316,200 shares [1] - Junxing Wulian's shareholder Fengtuohui has reduced 667,000 shares [1] - Mingxin Xuteng's shareholder Zhuang Yan has reduced 1.00% of company shares [1] Other Notable Events - Ganfeng Lithium is under investigation for suspected insider trading, with the case transferred to the procuratorate for review and prosecution [1] - Delisting of Suwu Company has been announced, with the company's stock terminated and delisted [1]

格隆汇12月29日丨毕得医药(688073.SH)公布，因股东自身流动性需求，股东李怡静、陈俊、李黎、杜 鹃、耿勇、蒋亚妹计划根据市场情况拟于本减持计划披露之日起3个交易日后的3个月内通过集中竞价方 式减持其所持有的公司股份，减持数量不超过公司总股本的0.95%。其中，李怡静减持公司股份数量不 超过282,520股，即不超过公司总股本的0.31%；陈俊减持公司股份数量不超过88,120股，即不超过公司 总股本的0.10%；李黎减持公司股份数量不超过200,000股，即不超过公司总股本的0.22%；杜鹃减持公 司股份数量不超过168,015股，即不超过公司总股本的0.18%；耿勇减持公司股份数量不超过100,000 股，即不超过公司总股本的0.11%。蒋亚妹减持公司股份数量不超过26,879股，即不超过公司总股本的 0.03%。减持价格将按照减持实际实施时的市场价格确定。 ...

格隆汇12月29日丨毕得医药(688073.SH)公布，近日，公司收到欣曦管理、兰旦管理、吴波出具的《关 于股份减持结果的告知函》，兰旦管理通过大宗交易的方式减持公司股份72.05万股，占公司总股本的 0.79%；欣曦管理通过大宗交易的方式减持公司股份30.19万股，占公司总股本的0.33%；吴波未减持公 司股份；前述股东合计减持公司股份102.24万股，占公司总股本的1.12%。本次减持计划时间区间已届 满。 ...

截至发稿，毕得医药市值为59亿元。 每经头条（nbdtoutiao）——绕开光刻机"卡脖子"，中国新型芯片问世！专访北大孙仲：支撑AI训练和 具身智能，可在28纳米及以上成熟工艺量产 每经AI快讯，毕得医药（SH 688073，收盘价：64.44元）12月29日晚间发布公告称，截至本公告披露 日，上海毕得医药科技股份有限公司股东李怡静持有公司无限售条件流通股约28万股，占公司股份总数 的0.31%。股东陈俊持有公司无限售条件流通股约8.81万股，占公司股份总数的0.1%。股东李黎持有公 司无限售条件流通股约21.45万股，占公司股份总数的0.24%。股东杜鹃持有公司无限售条件流通股约 16.8万股，占公司股份总数的0.18%。股东耿勇持有公司无限售条件流通股约12.3万股，占公司股份总 数的0.14%。股东蒋亚妹持有公司无限售条件流通股约2.69万股，占公司股份总数的0.03%。李怡静、陈 俊、李黎、杜鹃、耿勇、蒋亚妹，合计持有毕得医药0.99%的股份。 因股东自身流动性需求，股东李怡静、陈俊、李黎、杜鹃、耿勇、蒋亚妹计划根据市场情况拟于本减持 计划披露之日起3个交易日后的3个月内通过集中竞价方式减持其所持有 ...

证券代码：688073 证券简称：毕得医药 公告编号：2025-093 上海毕得医药科技股份有限公司 截至本公告披露日，上海毕得医药科技股份有限公司（以下简称"毕得医药" 或"公司"）股东李怡静持有公司无限售条件流通股 282,520 股，占公司股份总 数的 0.31%。股东陈俊持有公司无限售条件流通股 88,120 股，占公司股份总数的 0.10%。股东李黎持有公司无限售条件流通股 214,515 股，占公司股份总数的 0.24%。股东杜鹃持有公司无限售条件流通股 168,015 股，占公司股份总数的 0.18%。股东耿勇持有公司无限售条件流通股 123,016 股，占公司股份总数的 0.14%。股东蒋亚妹持有公司无限售条件流通股 26,879 股，占公司股份总数的 0.03%。李怡静、陈俊、李黎、杜鹃、耿勇、蒋亚妹，合计持有毕得医药 0.99% 的股份。 李怡静、陈俊、李黎、杜鹃、耿勇、蒋亚妹本次拟减持的股份系公司原股东 宁波鼎华永创创业投资合伙企业（有限合伙）（以下简称"鼎华永创"）解散后， 通过证券非交易过户的方式取得。 减持计划的主要内容 因股东自身流动性需求，股东李怡静、陈俊、李黎、杜鹃、耿勇、蒋 ...

证券代码：688073 证券简称：毕得医药 公告编号：2025-092 上海毕得医药科技股份有限公司 股东减持计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次股份减持计划实施前，上海毕得医药科技股份有限公司（以下简称"毕 得医药"或"公司"）股东舟山欣曦企业管理合伙企业（有限合伙）（以下简称"欣 曦管理"）持有公司无限售条件流通股 5,019,806 股，占公司股份总数的 5.52%。 股东宁波兰旦企业管理合伙企业（有限合伙）（现改名为"舟山兰旦企业管理合 伙企业（有限合伙）"，以下简称"兰旦管理"）持有公司股份 4,305,076 股，占 公司股份总数的 4.74%，其中 69,486 股为有限售条件流通股，4,235,590 股为无 限售条件流通股。股东吴波持有公司无限售条件流通股 785,804 股，占公司股份 总数的 0.86%。欣曦管理、兰旦管理、吴波系一致行动人，合计持有毕得医药 11.12%的股份。 欣曦管理、兰旦管理所持股份 ...

毕得医药公告，股东李怡静、陈俊、李黎、杜鹃、耿勇、蒋亚妹合计持股0.99%，拟于披露后3个交易 日后的3个月内以集中竞价减持不超公司总股本0.95%，其中李怡静不超28.25万股(0.31%)、陈俊不超 88120股(0.10%)、李黎不超20万股(0.22%)、杜鹃不超16.8万股(0.18%)、耿勇不超10万股(0.11%)、蒋亚 妹不超26879股(0.03%)，减持价格按届时市场确定。 ...